Aaron Pugh, DO
Gastroenterology · Newburgh, INNPI 1427245018
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Medtronic at 51.9% of the total. Reporting peaked in 2024 at $12,457 and has fallen 80.8% since, to $2,389 in 2025. Among gastroenterology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 529 payments — averaging $41.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$11K
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$943
- Johnson & Johnson$877
- Takeda Pharmaceuticals U.S.A., Inc.$874
- Gilead$653
- plus $4K from 28 others
What the payments were for
- Consulting fees$9,81445%
- Travel & lodging$1,1165%
- Food & beverage$11,07550%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 23 | $11,442 |
| AbbVie(2 entities) | 154 | $3,117 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 51 | $943 |
| Johnson & Johnson | 31 | $877 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $874 |
| Gilead | 32 | $653 |
| Bristol Myers Squibb | 44 | $558 |
| Pfizer | 20 | $443 |
| Intercept Pharmaceuticals, Inc. | 18 | $372 |
| Sanofi | 14 | $312 |
| Regeneron Healthcare Solutions, Inc. | 11 | $280 |
| Madrigal Pharmaceuticals | 7 | $238 |
| Ironwood Pharmaceuticals, Inc | 11 | $208 |
| Janssen Scientific Affairs, LLC | 2 | $158 |
| Ardelyx, Inc. | 8 | $154 |
| E.r. Squibb & Sons, L.L.C. | 1 | $140 |
| QOL Medical, LLC | 6 | $135 |
| Boston Scientific | 6 | $131 |
| Phathom Pharmaceuticals, Inc. | 7 | $117 |
| Merck | 6 | $108 |
| Organon | 5 | $102 |
| Daiichi Sankyo Inc. | 5 | $99 |
| Amgen | 5 | $94 |
| Shionogi Inc | 4 | $64 |
| Ferring Pharmaceuticals Inc. | 4 | $61 |
| Lilly USA, LLC | 3 | $59 |
| Braintree Laboratories, Inc. | 3 | $56 |
| Covidien LP | 1 | $48 |
| Shire North American Group Inc | 3 | $44 |
| AMAG Pharmaceuticals, Inc. | 2 | $36 |
| AstraZeneca | 3 | $34 |
| Aimmune Therapeutics, Inc. | 1 | $31 |
| Steris Corporation | 1 | $18 |
| Novo Nordisk | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,028 in reported general payments places this provider in the 90th percentile of 323 gastroenterology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 13 | $339,520 |
| Humira(Cf) PenAdalimumab | 11 | $74,790 |
| LinzessLinaclotide | 39 | $28,083 |
| MotegrityPrucalopride Succinate | 26 | $23,787 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 202 | $13,593 |
| DexilantDexlansoprazole | 21 | $8,784 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 36 | $6,174 |
| Pantoprazole Sodium | 271 | $3,032 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 98 | $2,146 |
| Sucralfate | 18 | $1,292 |
| Omeprazole | 85 | $911 |
| Dicyclomine Hcl | 30 | $526 |
| Ondansetron OdtOndansetron | 13 | $367 |
| Metoclopramide Hcl | 14 | $230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $877 | $339,52013 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant | $874 | $32,57147 claims |
| AbbVieLinzess | $3,117 | $28,08339 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $61 | $6,17436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 323 gastroenterology providers in Indiana.
Other gastroenterology in Newburgh
- Douglas RexIndianapolis$557K
- Ajay JainIndianapolis$432K
- Jonathan ObertNew Albany$302K
- Monika FischerIndianapolis$258K
- Naga ChalasaniIndianapolis$255K
- Matthew BohmWestfield$239K
- Thomas ImperialeIndianapolis$188K
- Mark GromskiIndianapolis$154K
- David PoundIndianapolis$137K
- Anoop AppannagariMunster$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.